Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida Glabrata with and without fks mutations

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5875-5882

  Lepak, Alexander ^a   Castanheira, Mariana ^c   Diekema, Daniel ^b   Pfaller, Michael ^b,c   Andes, David ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANDIDA GLABRATA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SCREENING; DRUG SENSITIVITY; FEMALE; FKS 1 GENE; FKS 2 GENE; FUNGUS ISOLATION; GENE; GENE MUTATION; IN VIVO STUDY; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUTANT; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; WILD TYPE;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CANDIDA GLABRATA; CANDIDIASIS, INVASIVE; ECHINOCANDINS; FEMALE; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HUMANS; KIDNEY; LIPOPEPTIDES; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 84868014787     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01102-12     Document Type: Article

References (56)

1. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79 - 86.
2. Andes D. 2005. Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy. Methods Mol. Med. 118:111-128.
3. Andes D, et al. 2011. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob. Agents Chemother. 55:2113-2121.
4. Andes D, Craig WA. 2005. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Eur. J. Clin. Microbiol. Infect. Dis. 11(Suppl. 6):10-17.
5. Andes D, et al. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54:2497-2506.
6. Andes D, et al. 2008. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:539-550.
7. Andes D, et al. 2004. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48:137-142.
8. Andes D, Marchillo K, Stamstad T, Conklin R. 2003. In vivo pharma-codynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:1193-1199.
9. Andes D, Marchillo K, Stamstad T, Conklin R. 2003. In vivo pharma-cokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
10. Andes D, van Ogtrop M. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43:2116-2120.
11. Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. 2008. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:3497-3503.
12. Andes DR, et al. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54: 1110-1122.
13. Arendrup MC, et al. 2012. Differential in vivo activity of anidulafungin, caspofungin, and micafungin against Candida glabrata with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56:2435-2442.
14. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. 2008. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 52:3022-3028.
15. Ben-Ami R, et al. 2011. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J. Infect. Dis. 204:626-635.
16. Castanheira M, et al. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659.
17. Chandrasekar PH, Sobel JD. 2006. Micafungin: a new echinocandin. Clin. Infect. Dis. 42:1171-1178.
18. Chapeland-Leclerc F, et al. 2010. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother. 54:1360-1362.
19. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49:3171-3177.
20. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
21. Clincal Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Costa-de-Oliveira S, et al. 2011. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidu-lafungin therapy. Antimicrob. Agents Chemother. 55:1312-1314.
23. Craig WA, Andes D. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:255-259.
24. Garcia-Effron G, et al. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54:2225-2227.
25. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
26. Gumbo T, et al. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn. Microbiol. Infect. Dis. 60:329-331.
27. Hebert MF, et al. 2005. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. 45:1145-1152.
28. Iatta R, Caggiano G, Cuna T, Montagna MT. 2011. Antifungal susceptibility testing of a 10-year collection of Candida spp. isolated from patients with candidemia. J. Chemother. 23:92-96.
29. Katiyar S, Pfaller M, Edlind T. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
30. Kofteridis DP, Lewis RE, Kontoyiannis DP. 2010. Caspofungin-non- susceptible Candida isolatesincancer patients. J. Antimicrob. Chemother. 65:293-295.
31. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. 2006. Am-photericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
32. Lee SC, et al. 2000. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob. Agents Chemother. 44:2715-2718.
33. Lee SY, Kuti JL, Nicolau DP. 2007. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J. Infect. 54:463-468.
34. Maglio D, et al. 2004. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob. Agents Chemother. 48: 1941-1947.
35. Pai MP, Turpin RS, Garey KW. 2007. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 51:35-39.
36. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
37. Park S, et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
38. Perlin D. 2011. Echinocandin-resistant Candida: molecular methods and phenotypes. Curr. Fungal Infect. Rep. 5:113-119.
39. Pfaller MA, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
40. Pfaller MA, et al. 2012. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata: results from the SENTRY Antimicrobial Surveillance Program (2006 to 2010) and the Centers for Disease Control and Prevention Population-Based Surveillance (2008 to 2010). J. Clin. Microbiol. 50:1199-1203.
41. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2010. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn. Microbiol. Infect. Dis. 68:278-283.
42. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
43. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
44. Pfaller MA, et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updates 14:164-176.
45. Pfaller MA, et al. 2009. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J. Clin. Microbiol. 47:3185-3190.
46. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. 2011. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int. J. Antimicrob. Agents 38:65-69.
47. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. 2011. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J. Clin. Microbiol. 49:396-399.
48. Pfeiffer CD, et al. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380.
49. Rex JH, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data forfluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24:235-247.
50. Rodriguez-Tudela JL, et al. 2007. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51:3599-3604.
51. Schmalreck AF, et al. 2012. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Mycoses 55:e124-e137.
52. Sun HY, Singh N. 2010. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents 35:211-218.
53. Takakura S, et al. 2004. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur. J. Clin. Microbiol. Infect. Dis. 23:380-388.
54. Thompson GR, III, et al. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.
55. Vazquez JA, Sobel JD. 2006. Anidulafungin: a novel echinocandin. Clin. Infect. Dis. 43:215-222.
56. Zimbeck AJ, et al. 2010. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob. Agents Chemother. 54:5042-5047.